Overview

Our lead T-cell therapy targets the NY-ESO peptide which is present across multiple cancer types. The NY-ESO TCR targets the NY-ESO-1 target peptide on cancer cells. NY-ESO-1 is one of the best-characterized and most immunogenic cancer testis antigens, and is frequently expressed by tumors of different origins and in advanced tumors.

In the U.S. we are conducting multiple Phase 1/2 clinical trials for our NY-ESO TCR therapeutic candidate in patients with solid tumors and hematological malignancies including synovial sarcoma, multiple myeloma, melanoma, NSCLC and ovarian cancer. We have seen responses and evidence of tumor reduction in patients with both synovial sarcoma and multiple myeloma. The initial data also suggests a promising risk/benefit profile. We continue to expand our clinical trials in the U.S. Submissions have also been made to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom and to Health Canada, which has now approved the clinical trial application.

We are developing our NY-ESO TCR therapeutic candidate in partnership with GSK. Read more about our strategic collaboration with GSK.

Pipeline

Candidate Indication Partner Development Stage
Research Pre-IND Phase 1/2
NY-ESO TCR Synovial Sarcoma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: High NY-ESO expression, 12 patients
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 2: Low NY-ESO expression, 10 patients
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 3: Removal of fludarabine, 5 patients 1
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 4: Modified CTX/fludarabine, 10 patients
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Myxoid Round Cell Liposarcoma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Multiple Myeloma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: Atuologous SCT, 25 patients.
Data published in N.Med.
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 2: Combination study: no auto JCT, 2 cohorts
Research Phase complete
Pre-IND Phase in progress
Phase 1/2 Phase not started
Ovarian GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: 10 patients, Modified CTX/fludarabine
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Melanoma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
NSCLC GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: 10pts, Stage IIIb / IV NSCLC
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Investigator Initiated Studies GSK
NCI: Synovial Sarcoma/Myeloma Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: Complete
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Investigator Initiated Studies GSK
ATTACK: Esophageal Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress

Our Clinical Trials